标题:Combinational strategies of metformin and chemotherapy in cancers
作者:Zhang, Hui-Hui; Guo, Xiu-Li
作者机构:[Zhang, Hui-Hui; Guo, Xiu-Li] Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, 44 Wen Hua Xi Rd, Jinan 250012, Peoples R China.
通讯作者:Guo, XL
通讯作者地址:[Guo, XL]Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, 44 Wen Hua Xi Rd, Jinan 250012, Peoples R China.
来源:CANCER CHEMOTHERAPY AND PHARMACOLOGY
出版年:2016
卷:78
期:1
页码:13-26
DOI:10.1007/s00280-016-3037-3
关键词:Metformin; Cancer; Chemotherapeutic agents; Combination therapy
摘要:Chemotherapeutic regimens are the most common treatment to inhibit tumor growth, but there is great variability in clinical responses of cancer patients; cancer cells often develop resistance to chemotherapeutics which results in tumor recurrence and further progression. Metformin, an extensively prescribed and well-tolerated first-line therapeutic drug for type 2 diabetes mellitus, has recently been identified as a potential and attractive anticancer adjuvant drug combined with chemotherapeutic drugs to improve treatment efficacy and lower doses. In this review, we summarized the molecular mechanisms underlying anticancer effects of metformin, which included insulin- and AMPK-dependent effects, selectively targeting cancer stem cells, reversing multidrug resistance, inhibition of the tumor metastasis and described the antineoplastic effects of metformin combined with chemotherapeutic agents in digestive system cancers (colorectal, gastric, hepatic and pancreatic cancer), reproductive system cancers (ovarian and endometrial cancer), prostate cancer, breast cancer, lung cancer, etc. Moreover, the clinical trials regarding metformin in combination of chemotherapeutic drugs were presented and the clinical obstacle or limitation related to the potential role of metformin in cancer treatment was also discussed in this review.
收录类别:SCOPUS;SCIE
WOS核心被引频次:25
Scopus被引频次:27
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978304034&doi=10.1007%2fs00280-016-3037-3&partnerID=40&md5=958a21c03da27aeb58edcc781e65daad
TOP